Cabergoline

Mohammed Rabie Osman Mahdy[1*], AmgadOsman Gohar[2],Hashem Fares Mohammed[3],Alaa GamalAbd Al Azeem[4], Mohamed Ahmed Ahmed[5]

Abstract

The syndrome nearly always presents either up to eight days once human chorionic gonadotrophin administration in vulnerable patients (early onset) or throughout early physiological state, nine or additional days once human chorionic gonadotrophin administration associated with physiological state evoked human chorionic gonadotrophin production.

Key Words: Treating Modalities, Cavum and Lungs, Gonadotrophin Injection.

DOI Number: 10.14704/nq.2022.20.8.NQ44453 **NeuroQuantology 2022; 20(8): 4195-4197**

Introduction

Ovarian hyperstimulation syndrome (OHSS) could be a dangerous induced complication of organic process induction (1). although it's a rare(2) or associate degree uncommon (3) condition its true incidence is troublesome to delineate as a strict accord definition is lacking (3). The incidence ranges from of thirty three you bored with gentle cases to 3-6 you bored with moderate cases whereas reaching solely 1-2% in severe cases(4,5). These severe cases ar grievous conditions that might be fatal. moreover, the pathophysiology of this condition isn't totally clear, understanding it helps distinctive preventive and treating modalities (6).

The syndrome nearly always presents either up to eight days when gonadotrophin administration in vulnerable patients (early onset) or throughout early physiological condition, nine or a lot of days when gonadotrophin administration associated with physiological condition iatrogenic gonadotrophin production(late onset(7). Early OHSS will to some extent be expected by pre-ovulatory indices of sex gland response, in time to institute preventive measures like cancellation(8). Late OHSS doesn't relate powerfully to pre-ovulatory sex gland response, creating it troublesome for clinicians to spot the cycles during which it's doubtless to occur (2,9).

Clinical options of OHSS embody a spectrum of findings, like sex gland enlargement, ascites, haemo-concentration, hyper-coagulability, and solution imbalances. serous membrane effusion, acute nephropathy and blood vessel thrombo - embolism occur in severe cases. A classification of OHSS symptoms was adopted by ASRM (3). Human chronic gonadotropine gonadotrophin administration for the ultimate vesicle maturation and organic process triggering is that the knock-out information for OHSS. This ends up in over expression of vascularepithelial tissue protein VEGF within the ovary, and unharness of vasoactive angiogenic substances or mediators that increase capillary porousness. After, fluid shift from the intra-to the extravascular areas withacute third-space fluid sequestration happens. This causes hemoconcentration with reduced organ introduction, alterations in clotting and therefore the ensuing risk of occlusion and outpouring of fluid into the cavum and lungs (3,6 &10,11).

The most necessary of those mediators is tube-shaped structure epithelial tissue protein (VEGF). VEGF may be a vasoactive intermediary that will increase capillary porosity.VEGF has been found to be expressed in human ovaries and is expressed at the next level within the granulosa cells (12).

Corresponding author: Mohammed Rabie Osman Mahdy
Address: [1*,2,3,4,5]Obstetrics & Gynaecology, Faculty of Medicine, Minia University, Egypt.

It's been discovered that VEGF ribonucleic acid

*e*ISSN1303-5150

levels will increase once human sac internal secretion (hCG) administration in granulosa cells and also the elevated levels of the secreted proteins are detected in blood serum, plasma, and serous membrane fluids in ladies in danger or with OHSS. VEGF stimulates new vas development and tube-shaped structure hyperpermeability by interacting with its VEGF receptor two (VEGFR2) (13,14). different factors that are concerned embrace angotensin II, interleukin-6, endocrine like protein one IGF-1, stratum protein, remodeling protein a and b, basic embryonic cell protein, thrombocyte driven protein lymphokine 1b et al. which might act directly or indirectly via VEGF (3).

No definite cure for this syndrome (15), interference is taken into account as a {vital|a necessary} and vital issue. each try ought to be done to spot those at high risk. 2 forms of interference are suggested; primary interference (before female internal reproductive organ stimulation) and secondary interference once female internal reproductive organ stimulation.(2). several preventive approaches are used for its interference together with victimization antagonist instead of agonists for organic process induction, triggering organic process with agonist, antidiabetic drug administration, blood vessel simple protein, cabergoline, corticosteroids, aspirin, coasting, cryopreservation et al., however the reports area unit conflicting and plenty of them haven't been critically evaluated (2,3).

There is growing proof that the ergot derivative; cabergoline that a potent Intropin receptor agonist on D2 administration reduces incidence and severity of OHSS (3). Intropin agonists stop the phosphorylation of VEGFR2 and scale back the in vitro and in vivo unleash of vasoactive angiogenic agents. As a result, tube-shaped structure porosity is additionally reduced. Consequently, Intropin agonist at a daily dose of zero.5 mg has been purported to be a possible new strategy to forestall OHSS and scale back its severity (16).

Results obtained with animal models (17), and also the safe clinical profile of Intropin agonists, have junction rectifier to studies on humans (16). Several studies have evaluated cabergoline as a preventive strategy to cut back the incidence of OHSS victimization varied doses and regimens (2,3 &10). Effectiveness of cabergoline in reduction of the incidence of OHSS was reportable in a gaggle of ladies with polycystic female internal reproductive organ syndromeand hyper -prolactinemia(18). Also, safety of cabergoline use throughout physiological conditiontreatment:fertilization,implantationand gestation rates were kind of like matched controls (19). Four systematic reviews and meta-analyses have unconcealed that cabergoline reduces the incidence of moderate/severe OHSS while not poignant implantation, gestation andmiscarriagerates(20,21,22 &23). 2 Cochrane reviews reportable that the standard of proof concerning the utilization Intropin agonist versus placebo in interference of female internal reproductive organ hyperstimulation ranged from terribly low to moderate (15,24). On the opposite hand,others reportablethat there's sensible proof that Intropin agonist administration beginning at the time of gonadotrophintrigger for many days scale back the incidence of OHSS(gradeA) (3).

Various cabergoline administration protocols were reportable in several studies.Doses were starting from zero.25 mg- 0.5 mg and were started either from day of gonadotrophin triggering or day of gametocyte retrieval. (16-23 & 25-28).Cabergoline was continuedkind 2 days in one study (27) and up to eight days in most studies (25,28)or as long as 3 weeks in one study (26).Alveizer et al.,(25)gave zero.5 mg cabergoline daily for eight days from the day of gonadotrophin injection.Carriza et al. (26) gave zero.5 mg cabergoline daily for three weeks from the day once gametocyte retrieval. salaat Edeen and Alhelou (27) used zero.5 mg cabergoline oral on two consecutive days and perennial once one week ranging from the day of gonadotrophin. Shaltout et al. 28) used zero.25 mg cabergoline daily for eight days from the day of gonadotrophin injection.

The influence of temporal order of cabergoline initiation on interference of OHSS is presently underneath study (29).

References

Kumar,P., Sait, S.F., Sharma,A., Kumar M.,Ovarian hyperstumulation syndrome. J.Hum.Reprod.Sci., 2011, 4,pp. 70-75.

Sallam, H.H., Ezzeldin F., Sallam, N.H.Prevention of OHSS-Anevidence-based approach.WARM 2010, S17-18.

Practice committee of the American Society for Reproductive Medicine Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guidelineFertil. Steril., 2016,106(7), 1634-1647.

R.S. Morris, C. Miller, L. Jacobs, K. MillerConservative management ofovarian hyperstimulation syndromeJ. Reprod. Med.,40 (1995), pp. 711-714.

Golan, R. Ron-El, A. Herman, Y. Soffer, Z. Weinraub, E. Caspi Ovarian hyperstimulation syndrome: an update review Obstet. Gynecol. Surv., 44 (1989), pp. 430-440.

Busso, C.E., Soares, S.R., Pellicer A.,Management of ovarian hyperstimulation syndrome- UpToDate2018.

Lyons CA. Wheeler CA. Frishman GN, Hackctl RJ, Scifcr DB and Hanning RVJ Early and late presentation of the ovarian hypcrstimulation syndrome: two distinct entities with different risk factors. Hum Reprod., 1994; 9, 792-799.

Hancock KW, Stitch SR, Oakey R, Scott JS, Levell MJ and Ellis PR Ovulation induction. Problems of prediction of response to gonadolrophin. Lancet 1970;2,482-485.

Mathur RS, Akande AV, Kcay SD et al. Late onset OHSS after ovarian stimulation is poorly predicted by peak ocstradiol concentration and number of oocytes collected. Hum Reprod 1997; 12 (Abslr Book I), R-229.

Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod., Update 2008;14:321-33.

D.D. Braat, J.M. Schutte, R.E. Bernardus, T.M. Mooij, F.E. Van Leeuwen Maternal death related to IVF in the Netherlands 1984–2008 Hum. Reprod., 25 (2010), pp. 1782-1786.

Naredi N, Talwar P, Sandeep K. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. Med J Armed Forces India 2014;70:58-63.

Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, et al.Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab., 2002;87:3300-8.

Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al.Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). Areassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem., 2001;276:3222-30.

Tang,H., Mourad, S., Zahi., S., Hart,R.J., Dopamine agonists to prevent ovarian hyperstim,ulation syndrome in women undergoing assisted reproduction technology Cochrane Database of systemic reviews, 2016 issue 11.

Shaltout A, Shohyab A, Youssef MA. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur J ObstetGynecolReprod Biol., 2012;165:254-8.

Ata B, Seyhan A, Orhaner S, Urman B. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril., 2009;92:1168.e1-4.

E. Papaleo, N. Doldi, L. DeSantis, G. Marelli, E. Marsiglio, S. Rofena, A. Ferrari Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome Hum. Reprod., 16 (2001), pp. 2263-2266 Cross Ref View Record in Scopus Google Scholar.

C. Alvarez, I. AlonsoMuriel, G. García, J. Crespo, J. Bellver, C. Sim ón, A. PellicerImplantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome (OHSS) in women undergoing ART. A pilot study Hum. Reprod.,22 (2007), pp. 3210-3214.

V.M. Leitao, R.M. Moroni, L.M. Seko, C.O. Nastri, W.P. Martins Cabergoline for the prevention of ovarian hyperstimulationsyndrome: systematic review and meta-analysis of randomized controlled trials Fertil. Steril., 101 (2014), pp. 664-675

M. Baumgarten, L. Polanski, B. Campbell, N. Raine-Fenning Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysisHum. Fertil. (Camb.), 16 (2013), pp. 168-174

H. Tang, T. Hunter, Y. Hu, S.D. Zhai, X. Sheng, R.J. Hart Cabergoline for preventing ovarian hyperstimulation syndrome Cochrane Database Syst. Rev., 15 (2) (2012), p. CD008605.

M.A. Youssef, M. VanWely, M.A. Hassan, H.G. AlInany, M. Mochtar, S. Khattab, et al.Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis Hum. Reprod. Update, 16 (2010), pp. 459-466.

Mourad S., Brown., J., Farquhar,C., Interventions for the prevention of ohss in ARTcycles: an overview of Cochrane reviews. Cochrane Database of systemic reviews. 2017. Issue 1.

Alvarez C, Marti-Bonmati L., Novella-Maestre E Sanz R., Gomez Fernandez-Sanchez M Simon C Pellicer.,A Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction J Clin Endocrinol Metab., 2007, vol.92, (pg.2931- 2937).

Carizza C.,Abdelmassih V.,Abdelmassih S., RavizziniSalgueiro L Salgueiro PT Jine LT Nagy P Abdelmassih RCabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study Reprod Biomed Online 2008, vol. 17 (pg.751- 755).

Salah Edeen AMRAlhelou YM Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone Abstracts of the 25th Annual Meeting of ESHRE 28 June–1 July 2009 Amsterdam, The Netherland.

Shaltout A ShohayebA Eid M Abbas S Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome Abstracts of the 25th Annual Meeting of ESHRE 28 June–1 July 2009 Amsterdam, The Netherland.

Shaban, M.,TheInfluence of Timing ofCabergoline Initiation on Prevention of OHSS. Dec 3, 2015 - Ovarian Hyperstimulation Syndrome, Drug: LateCabergoline0.5mg Drug: Early... With adjustments of gonadotropin dose and monitoring frequency based on.... Keywords provided by Mona M Shaban, Cairo University.